Literature DB >> 20182420

Impact of CYP4F2 rs2108622 on the stable warfarin dose in an admixed patient cohort.

J A Perini1, C J Struchiner, E Silva-Assunção, G Suarez-Kurtz.   

Abstract

There is controversy regarding the association between the CYP4F2 rs2108622 (V33M) polymorphism and warfarin dose requirement in white patients, and there are no data for nonwhite populations. We observed no association in self-identified white, black, or "intermediate" Brazilian patients (n = 370). The addition of the rs2108622 genotype as a variable has only a marginal effect on the predictive power of a warfarin dosing algorithm derived from this patient cohort. We conclude that prospective CYP4F2 genotyping is not justified in Brazilians who are potential candidates for warfarin therapy.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20182420     DOI： 10.1038/clpt.2009.307

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  22 in total

Review 1.  Implications of pharmacogenetic testing for patients taking warfarin or clopidogrel.

Authors:  Megan M Donohue; David L Tirschwell
Journal:  Curr Neurol Neurosci Rep       Date:  2011-02       Impact factor: 5.081

2.  Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 Individuals.

Authors:  Elisa Danese; Sara Raimondi; Martina Montagnana; Angela Tagetti; Taimour Langaee; Paola Borgiani; Cinzia Ciccacci; Antonio J Carcas; Alberto M Borobia; Hoi Y Tong; Cristina Dávila-Fajardo; Mariana Rodrigues Botton; Stephane Bourgeois; Panos Deloukas; Michael D Caldwell; Jim K Burmester; Richard L Berg; Larisa H Cavallari; Katarzyna Drozda; Min Huang; Li-Zi Zhao; Han-Jing Cen; Rocio Gonzalez-Conejero; Vanessa Roldan; Yusuke Nakamura; Taisei Mushiroda; Inna Y Gong; Richard B Kim; Keita Hirai; Kunihiko Itoh; Carlos Isaza; Leonardo Beltrán; Enrique Jiménez-Varo; Marisa Cañadas-Garre; Alice Giontella; Marianne K Kringen; Kari Bente Foss Haug; Hye Sun Gwak; Kyung Eun Lee; Pietro Minuz; Ming Ta Michael Lee; Steven A Lubitz; Stuart Scott; Cristina Mazzaccara; Lucia Sacchetti; Ece Genç; Mahmut Özer; Anil Pathare; Rajagopal Krishnamoorthy; Andras Paldi; Virginie Siguret; Marie-Anne Loriot; Vijay Kumar Kutala; Guilherme Suarez-Kurtz; Jamila Perini; Josh C Denny; Andrea H Ramirez; Balraj Mittal; Saurabh Singh Rathore; Hersh Sagreiya; Russ Altman; Mohamed Hossam A Shahin; Sherief I Khalifa; Nita A Limdi; Charles Rivers; Aditi Shendre; Chrisly Dillon; Ivet M Suriapranata; Hong-Hao Zhou; Sheng-Lan Tan; Vacis Tatarunas; Vaiva Lesauskaite; Yumao Zhang; Anke H Maitland-van der Zee; Talitha I Verhoef; Anthonius de Boer; Monica Taljaard; Carlo Federico Zambon; Vittorio Pengo; Jieying Eunice Zhang; Munir Pirmohamed; Julie A Johnson; Cristiano Fava
Journal:  Clin Pharmacol Ther       Date:  2019-02-17       Impact factor: 6.875

3.  Impact of incorporating ABCB1 and CYP4F2 polymorphisms in a pharmacogenetics-guided warfarin dosing algorithm for the Brazilian population.

Authors:  Letícia C Tavares; Nubia E Duarte; Leiliane R Marcatto; Renata A G Soares; Jose E Krieger; Alexandre C Pereira; Paulo Caleb Junior Lima Santos
Journal:  Eur J Clin Pharmacol       Date:  2018-07-26       Impact factor: 2.953

4.  Race-Specific Influence of CYP4F2 on Dose and Risk of Hemorrhage Among Warfarin Users.

Authors:  Aditi Shendre; Todd M Brown; Nianjun Liu; Charles E Hill; T Mark Beasley; Deborah A Nickerson; Nita A Limdi
Journal:  Pharmacotherapy       Date:  2016-03-14       Impact factor: 4.705

5.  Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients.

Authors:  Mohamed Hossam A Shahin; Sherief I Khalifa; Yan Gong; Lamiaa N Hammad; Mohamed T H Sallam; Mostafa El Shafey; Shawky S Ali; Mohamed-Eslam F Mohamed; Taimour Langaee; Julie A Johnson
Journal:  Pharmacogenet Genomics       Date:  2011-03       Impact factor: 2.089

6.  Effect of the VKORC1 D36Y variant on warfarin dose requirement and pharmacogenetic dose prediction.

Authors:  Daniel Kurnik; Husam Qasim; Sophie Sominsky; Aharon Lubetsky; Noa Markovits; Chun Li; C Michael Stein; Hillel Halkin; Eva Gak; Ronen Loebstein
Journal:  Thromb Haemost       Date:  2012-08-07       Impact factor: 5.249

Review 7.  Pharmacogenomics of anti-platelet and anti-coagulation therapy.

Authors:  Adam S Fisch; Christina G Perry; Sarah H Stephens; Richard B Horenstein; Alan R Shuldiner
Journal:  Curr Cardiol Rep       Date:  2013-07       Impact factor: 2.931

Review 8.  PharmGKB summary: very important pharmacogene information for CYP4F2.

Authors:  Maria L Alvarellos; Katrin Sangkuhl; Roxana Daneshjou; Michelle Whirl-Carrillo; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2015-01       Impact factor: 2.089

Review 9.  Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?

Authors:  Mohamed H A Shahin; Julie A Johnson
Journal:  Curr Opin Cardiol       Date:  2013-05       Impact factor: 2.161

10.  Influence of ORM1 polymorphisms on the maintenance stable warfarin dosage.

Authors:  Lian Sheng Wang; Jing Jing Shang; Shu Ya Shi; Yan Qing Zhang; Jian Lin; Zhi Hua Guo; Yi Chen Wang; Jie Tang; Jie Liu; Ying Zi Liu; Zhi Li; Zhi Rong Tan; Hong Hao Zhou; Hai He Jiang; Hai Tang Xie
Journal:  Eur J Clin Pharmacol       Date:  2012-12-04       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.